Lapatinib Stada Arzneimittel Ag (Lapatinib)

Lapatinib blocks the intracellular tyrosine kinase activity of both EGFR (ErbB1) and HER2 (ErbB2). By inhibiting these receptors, it disrupts downstream signaling pathways such as MAPK and PI3K/AKT, which are essential for tumor cell proliferation and survival.

The exact dose of Lapatinib is determined by the prescribing physician based on the patient’s clinical condition, prior therapies, liver function, and potential drug interactions. No fixed regimen is provided here; dosing decisions are individualized by the healthcare professional.

Safety data for Lapatinib in pregnancy and lactation are limited. It is generally contraindicated unless the potential benefit justifies the risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their oncologist.

To request Lapatinib, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lapatinib is a small‑molecule oral inhibitor, whereas agents like trastuzumab and pertuzumab are monoclonal antibodies administered intravenously. Lapatinib offers the convenience of oral dosing and can be combined with other oral agents, but its safety profile and resistance patterns differ from antibody‑based treatments.

Lapatinib tablets should be stored at or below 25 °C in their original container, protected from moisture and light. Keep the product out of reach of children and avoid exposing it to extreme temperatures or humidity.

Lapatinib is taken orally, usually with a low‑fat meal to improve absorption. The tablet should be swallowed whole with water and not crushed or chewed. Patients should follow the specific administration instructions provided by their prescriber.

Serious adverse events include hepatotoxicity, cardiac dysfunction such as reduced left ventricular ejection fraction, severe skin reactions like Stevens‑Johnson syndrome, and QT‑interval prolongation that can lead to arrhythmias. Prompt medical evaluation is required if any of these symptoms appear.

Lapatinib should be avoided in patients with known hypersensitivity to the drug, severe hepatic impairment, uncontrolled cardiac disease, or those taking strong CYP3A4 inducers that could markedly reduce its effectiveness. Clinicians must assess each individual’s medical history before initiating therapy.